Exploring bleeding risk and platelet function combined with multiple omics techniques in 22q11.2 deletion syndrome - Platelet function in 22q11.2DS

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年4月9日

适应症

试验速览

暂无简介。

•- 16 years or older.
•- signed informed consent.
•Adults with 22q11.2DS
•- molecularly confirmed 22q11.2 deletion syndrome.
•- Mentally competent (ability to give informed consent) and aged 16 years and
•older or, in case
•the individual is mentally incompetent aged 16 years and older, consent will be
•given by the legally authorized representative of the subject.

•- The presence of any malignancy.
•- Use of antiplatelet or anticoagulant drugs within the last two weeks prior to
•- Use of anti-inflammatory drugs within the last two weeks prior to the study.
•- auto-immune thrombocytopenia
•Specific for healthy controls:
•- A medical history of thrombocytopenia (<150.000 platelets per mL).
•- Increased bleeding risk, defined as a diagnosed bleeding disorder.
•- Metabolic disorder.

发起方

Medisch Universitair Ziekenhuis Maastricht